Factors influencing the failure of interferon-free therapy for chronic hepatitis C: Data from the Polish EpiTer-2 cohort study

Table 2 Baseline characteristics of patients with and without sustained virologic response and their relationship to treatment efficacy-laboratory parameters

Variable	Total, n = 11938	SVR, n = 11629	Non-SVR, n = 309	P value
Albumin (g/dL)	4.37 (4.2-4.45)	4.38 (4.29-4.46)	4.02 (3.76-4.28)	< 0.001
Bilirubin (mg/dL)	0.80 (0.79-0.81)	0.79 (0.78-0.80)	1.06 (0.98-1.15)	< 0.001
INR	1.10 (1.07-1.12)	1.10 (1.07-1.12)	1.11 (1.08-1.13)	< 0.001
PLT (K/μL)	191.47 (190.07-192.85)	192.62 (191.22-194.02)	147.63 (139.07-156.19)	< 0.001
ALT (U/L)	78.39 (77.19-79.59)	77.92 (76.71-79.13)	96.07 (87.16-104.98)	< 0.001
Creatinine (mg/dL)	0.92 (0.89-0.96)	0.93 (0.89-0.96)	0.81 (0.79-0.83)	0.749
eGFR, n (%)
< 30 mL/min	137 (29.2)	137 (29.7)	0 (0.0)
> 60 mL/min	160 (34.0)	157 (34.0)	3 (37.5)	0.252
30-60 mL/min	173 (36.8)	168 (36.3)	5 (62.5)
Hemoglobin (g/dL)	14.40 (14.37-14.43)	14.40 (14.37-14.44)	14.35 (14.15-14.55)	0.812
HCV genotype, n (%)
1A	434 (3.6)	426 (3.7)	8 (2.6)
1B	9327 (78.1)	9147 (78.7)	180 (58.3)
2	20 (0.2)	20 (0.2)	0 (0.0)	< 0.001
3	1328 (11.1)	1221 (10.5)	107 (34.6)
4	575 (4.8)	565 (4.9)	10 (3.2)
5	1 (0.0)	1 (0.0)	0 (0.0)
6	2 (0.0)	2 (0.0)	0 (0.0)
HCV RNA (log10)	6.37 (6.34-6.39)	6.36 (6.34-6.39)	6.39 (6.31-6.46)	0.004

SVR: Sustained virologic response; INR: International normalized ratio; PLT: Platelets; ALT: Alanine aminotransferase; eGFR: Estimated glomerular filtration rate; HCV: Hepatitis C virus.